ArticleTherapeutic advances in medical oncology2026
Clinical outcomes and genomic landscape of anti-HER2 antibody-drug conjugates in HER2-positive and HER2-low metastatic breast cancer.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates (ADCs) have revolutionized the treatment for HER2-positive and HER2-low metastatic breast cancer (MBC). However, the comparative efficacy, safety, and molecular predictors of response to various anti-HER2 ADCs remain limited. Objectives: To evaluate real-world clinical outcomes, safety profiles, and genomic alterations associated with response to anti-HER2 ADCs in patients with HER2-positive or HER2-low MBC. Design: Retrospective single-center cohort study. Methods: Patients with HER2-positive or HER2-low MBC who received anti-HER2 ADCs (T-DXd, SHR-A1811, RC48, or T-DM1) between September 1, 2020, and September 1, 2024, were enrolled. Progression-free survival (PFS), overall survival, objective response rate (ORR), and safety were assessed. Targeted next-generation sequencing was performed to identify genomic correlates of response. Results: A total of 322 patients were included, comprising 183 HER2-positive and 139 HER2-low cases. The ORR in the HER2-positive group and the HER2-low group were 32.8% versus 20.8%, respectively, and median PFS were 9.9 months versus 4.1 months. Median PFS in the T-DXd, SHR-A1811, RC48, and T-DM1 groups were 9.3 months, 25.8 months, 3.2 months, and 7.6 months, respectively (p<0.001). HER2 expression, prior lines of therapy, and ADC type independently predicted PFS. Common adverse events included hematologic toxicity, fatigue, and nausea; pneumonitis occurred in 7.3% of T-DXd recipients. Genomic profiling identified Conclusions: This study provides descriptive real-world data on four anti-HER2 ADCs in HER2-positive and HER2-low MBC. Distinct genomic alterations, especially
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.